Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n= 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n= 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
Size: 4.0 MB